Program
tezacaftor
Also written as “ELX/TEZ/IVA”, “TEZ/IVA” and “TEZ”.
Its studies are mostly in Cystic Fibrosis, led by Vertex Pharmaceuticals.
Drug pageTezacaftor: every studyAll 43 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 394 open or running | phase 3since Jan 12, 2015 | Feb 1, 2012 | Apr 6, 2027phase 3 · NCT05331183 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 26 earlier studies, Feb 1, 2012 to Apr 16, 2020.
- Dec 9, 2015Named tezacaftorINNProposed as its International Nonproprietary Name in WHO's List 114 · before, VX-661
- Aug 28, 2020Phase 3 study in Cystic FibrosisNCT04537793 · 83 enrolled · United States, Australia, Canada and more
- Sep 3, 2020Phase 3 study in Cystic FibrosisNCT04545515 · 120 enrolled · Australia, Canada, Denmark and more
- Oct 21, 2020Phase 3 study in Cystic FibrosisNCT04599465 · 69 enrolled · Australia, Belgium, Czechia and more
- Jul 9, 2021Phase 3 study in Cystic FibrosisNCT04969224 · 82 enrolled · Australia, Belgium, Canada and more
- Oct 27, 2021Phase 3 study in Cystic FibrosisNCT05111145 · 86 enrolled · Australia, Belgium, Canada and more
- Nov 29, 2021Phase 3 study in Cystic FibrosisNCT05153317 · 71 enrolled · United States, Australia, Canada and more
- Mar 1, 2022Phase 3 study in Cystic FibrosisNCT05274269 · 307 enrolled · Austria, Belgium, Canada and more
- Apr 8, 2022Phase 3 study in Cystic FibrosisNCT05331183 · 297 enrolled · Austria, Belgium, Canada and more
- May 19, 2023Phase 3 study in Cystic FibrosisNCT05882357 · 67 enrolled · Australia, Canada, Denmark and more
- Nov 23, 2023Phase 1 study in Cystic FibrosisNCT06154447 · 165 enrolled · United States
- Jun 10, 2024Phase 3 study in Cystic FibrosisNCT06460506 · 50 enrolled · Australia, Canada, Denmark and more
- Dec 4, 2025Phase 1 study in Cystic FibrosisNCT07283770 · 152 planned · United States
- Feb 20, 2026Phase 1 study in Cystic FibrosisNCT07437105 · 160 planned · United States
- Oct 19, 2026Primary completion moved from 2026-11-19 to 2027-07-12Date moved laterphase 1 · +8 months · NCT07283770
Ahead
- Apr 6, 2027Primary completion: phase 3 study in Cystic FibrosisNCT05331183
- Jun 26, 2027Primary completion: phase 1 study in Cystic FibrosisNCT07437105
- Jul 12, 2027Primary completion: phase 1 study in Cystic FibrosisNCT07283770
- Sep 30, 2027Primary completion: phase 3 study in Cystic FibrosisNCT06460506
TargetBeta
“Cystic fibrosis transmembrane conductance regulator positive modulator”ChEMBL 37, by rule
Other programs on CFTR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivacaftorrule | Vertex Pharmaceuticals | phase 4 | 78 |
| lumacaftorrule | Vertex Pharmaceuticals | phase 4 | 23 |
Studies
All 39 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07437105Cystic Fibrosis · United States | 1 | Recruiting | Jun 26, 2027 | 160 |
| NCT07283770Cystic Fibrosis · United States | 1 | Recruiting | Jul 12, 2027 | 152 |
| NCT06460506Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Active, not recruiting | Sep 30, 2027 | 50 |
| NCT06154447Cystic Fibrosis · United States | 1 | Completed | Jul 10, 2026 | 165 |
| NCT05882357Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Completed | Sep 4, 2025 | 67 |
| NCT05331183Cystic Fibrosis · Austria, Belgium, Canada and more | 3 | Active, not recruiting | Apr 6, 2027 | 297 |
| NCT05274269Cystic Fibrosis · Austria, Belgium, Canada and more | 3 | Completed | Jul 5, 2023 | 307 |
| NCT05153317Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Jan 29, 2026 | 71 |
| NCT05111145Cystic Fibrosis · Australia, Belgium, Canada and more | 3 | Completed | Dec 20, 2022 | 86 |
| NCT04969224Cystic Fibrosis · Australia, Belgium, Canada and more | 3 | Completed | Jul 26, 2022 | 82 |
| NCT04599465Cystic Fibrosis · Australia, Belgium, Czechia and more | 3 | Completed | Jul 14, 2022 | 69 |
| NCT04545515Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Completed | Mar 24, 2023 | 120 |
| NCT04537793Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Jun 3, 2022 | 83 |
| NCT04362761Cystic Fibrosis · Australia, Belgium, Germany and more | 3 | Completed | Dec 21, 2022 | 172 |
| NCT04353817Cystic Fibrosis · Australia, Canada, Denmark and more | 3 | Completed | May 17, 2021 | 121 |
| NCT04183790Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Feb 24, 2024 | 64 |
| NCT04058366Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Dec 16, 2022 | 251 |
| NCT03768089Cystic Fibrosis · Netherlands, United Kingdom | 2 | Completed | May 3, 2019 | 115 |
| NCT03691779Cystic Fibrosis · United States, Australia, Canada and more | 3 | Completed | Aug 7, 2020 | 71 |
| NCT03559062Cystic Fibrosis · Australia, Belgium, Denmark and more | 3 | Completed | Dec 21, 2018 | 67 |
| NCT03537651Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Oct 28, 2020 | 130 |
| NCT03525574Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Jan 9, 2023 | 507 |
| NCT03486236Cystic Fibrosis · United Kingdom | 1 | Completed | Sep 14, 2016 | 16 |
| NCT03227471Cystic Fibrosis · United States, Australia, Belgium and more | 2 | Completed | Mar 27, 2018 | 225 |
| NCT03224351Cystic Fibrosis · United States, Ireland, Israel and more | 2 | Completed | Feb 28, 2018 | 124 |
| NCT03150719Cystic Fibrosis · United States, France, Germany | 3 | Completed | Aug 9, 2018 | 98 |
| NCT02951195Cystic Fibrosis · United States | 2 | Completed | Jan 2018 | 80 |
| NCT02951182Cystic Fibrosis · United States, Australia, Austria and more | 2 | Completed | Aug 2017 | 74 |
| NCT02953314Cystic Fibrosis · United States, Canada | 3 | Completed | Sep 2018 | 83 |
| NCT02730208Cystic Fibrosis · Australia | 2 | Completed | Jul 2018 | 41 |
| NCT02565914Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | May 2019 | 1,131 |
| NCT02516410Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Jun 7, 2016 | 168 |
| NCT02508207Cystic Fibrosis · United States | 2 | Completed | Jun 2017 | 34 |
| NCT02412111Cystic Fibrosis · United States, Australia, Austria and more | 3 | Completed | Sep 2017 | 156 |
| NCT02392234Cystic Fibrosis · United States, Australia, Belgium and more | 3 | Completed | Feb 2017 | 248 |
| NCT02347657Cystic Fibrosis · United States, Canada, Denmark and more | 3 | Completed | Jan 20, 2017 | 510 |
| NCT02070744Cystic Fibrosis · United States | 2 | Completed | May 27, 2016 | 40 |
| NCT02015507Cystic Fibrosis | 1 | Completed | Feb 2014 | 34 |
| NCT01531673Cystic Fibrosis · United States, Canada, Germany and more | 2 | Completed | Mar 2014 | 194 |
How it is read
Names in the registry
- “ELX/TEZ/IVA”, 16 entries
- “TEZ/IVA”, 8 entries
- “TEZ”, 4 entries
- “Tezacaftor/Ivacaftor”, 4 entries
- “VX-661”, 3 entries
Codes read as this program: VX661.
Conditions, from the studies’ own filings
- Cystic Fibrosis, 39 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.